(alphaR)-alpha-环丙基苯甲胺盐酸盐 | 1416450-04-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (alphaR)-alpha-环丙基苯甲胺盐酸盐
• 中文别名: (R)-苯基环丙基甲胺盐酸盐
• 英文名称: (R)-cyclopropylphenylmethylamine hydrochloride
• 英文别名: (R)-N-cyclopropyl-N-phenylmethylamine hydrochloride；(1R)-1-cyclopropyl-1-phenylmethanamine hydrochloride；(R)-cyclopropyl(phenyl)methanamine hydrochloride；(R)-cyclopropyl(phenyl)methanamine;hydrochloride
• CAS: 1416450-04-8
• 化学式: C₁₀H₁₃N*ClH
• 分子量: 183.681
• InChiKey: QTUNRTDRPMOQNG-PPHPATTJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.52
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  2,6-dichloro-9-((3aR,3bR,4aS,5R,5aS)-2,2-dimethylhexahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxol-5-yl)-9H-purine 、 (alphaR)-alpha-环丙基苯甲胺盐酸盐 在 三乙胺 作用下， 以 甲醇 为溶剂， 以81%的产率得到(1R,2R,3S,4R,5S)-4-(2-chloro-6-((R)-N-cyclopropyl-N-phenylmethylamino)-9H-purin-9-yl)-2,3-O-(isopropylidene)bicyclo[3.1.0]hexane
  参考文献：
  名称：

  Structural Sweet Spot for A₁ Adenosine Receptor Activation by Truncated (N)-Methanocarba Nucleosides: Receptor Docking and Potent Anticonvulsant Activity

  摘要：

  A(1) adenosine receptor (AR) agonists display antiischemic and antiepileptic neuroprotective activity, but peripheral cardiovascular side effects impeded their development. SAR study of N-6-cycloalkylmethyl 4'-truncated (N)-methanocarba-adenosines identified 10 (MRS5474, N-6-dicyclopropylmethyl, K-i = 47.9 nM) as a moderately A(1)AR-selective full agonist. Two stereochemically defined N-6-methynyl group substituents displayed narrow SAR; groups larger than cyclobutyl greatly reduced AR affinity, and those larger or smaller than cyclopropyl reduced A(1)AR selectivity. Nucleoside docking to A(1)AR homology model characterized distinct hydrophobic cyclopropyl subpockets, the larger "A" forming contacts with Thr270 (7.35), Tyr271 (7.36), Ile274 (7.39), and carbon chains of glutamates (EL2) and the smaller subpocket "B" forming contacts between TM6 and TM7. 10 suppressed minimal clonic seizures (6 Hz mouse model) without typical rotarod impairment of A(1)AR agonists. Truncated nucleosides, an appealing preclinical approach, have more druglike physicochemical properties than other A(1)AR agonists. Thus, we identified highly restricted regions for substitution around N-6 suitable for an A(1)AR agonist with anticonvulsant activity.

  DOI：

  10.1021/jm300965a

文献信息

• NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP3135674A1

  公开（公告）日：2017-03-01

  The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X1 and X2 is a carbon atom, and the other is a nitrogen atom, X3 is a nitrogen atom, or CR2, X4 is a nitrogen atom, or CR3, X5 is a sulfur atom, or -CH=CH-, Z1 is an oxygen atom, -C(R6)(R7)-, -NH-, -C(R6)(R7)-NH-,-NH-C(R6)(R7)-, -C(R6)(R7)-O-, -O-C(R6)(R7)-, or a single bond, one of Z2 and Z3 is CH and the other is a nitrogen atom, or both are nitrogen atoms, and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.

  本发明提供了一种由式 (I) 表示的新型双环或三环杂环化合物 其中环 A 是任选取代的芳香基团、 X1 和 X2 中的一个是碳原子，另一个是氮原子、 X3 是氮原子或 CR2、 X4 是氮原子或 CR3、 X5 是硫原子，或 -CH=CH-、 Z1 是氧原子、-C(R6)(R7)-、-NH-、-C(R6)(R7)-NH-、-NH-C(R6)(R7)-、-C(R6)(R7)-O-、-O-C(R6)(R7)- 或单键、 Z2 和 Z3 中的一个是 CH 原子，另一个是氮原子，或两个都是氮原子、 和其他符号如在 DESCRIPTION 中所定义，或其药理上可接受的盐。
• BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS
  申请人：KPC Pharmaceuticals, Inc.

  公开号：EP3816158A1

  公开（公告）日：2021-05-05

  The present invention relates to benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof.

  本发明涉及苯并咪唑化合物及其作为IDH1突变体抑制剂的应用，特别是涉及由式（I）代表的化合物、其同系物或其药学上可接受的盐。
• Bicyclic or tricyclic heterocyclic compound
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US10065972B2

  公开（公告）日：2018-09-04

  The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X1 and X2 is a carbon atom, and the other is a nitrogen atom, X3 is a nitrogen atom, or CR2, X4 is a nitrogen atom, or CR3, X5 is a sulfur atom, or —CH═CH—, Z1 is an oxygen atom, —C(R6)(R7)—, —NH—, —C(R6)(R7)—NH—, —NH—C(R6)(R7)—, —C(R6)(R7)—O—, —O—C(R6)(R7)—, or a single bond, one of Z2 and Z3 is CH and the other is a nitrogen atom, or both are nitrogen atoms, and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.

  本发明提供了一种由式 (I) 表示的新型双环或三环杂环化合物 其中环 A 是任选取代的芳香基团、 X1 和 X2 中的一个是碳原子，另一个是氮原子、 X3 是氮原子或 CR2、 X4 是氮原子，或 CR3、 X5 是硫原子，或-CH═CH-、 Z1 是氧原子、-C(R6)(R7)-、-NH-、-C(R6)(R7)-NH-、-NH-C(R6)(R7)-、-C(R6)(R7)-O-、-O-C(R6)(R7)- 或单键、 Z2 和 Z3 中的一个是 CH 原子，另一个是氮原子，或两个都是氮原子、 和其他符号如在 DESCRIPTION 中所定义，或其药理上可接受的盐。
• Benzimidazole derivatives and use thereof as IDH1 inhibitors
  申请人：KPC PHARMACEUTICALS, INC.

  公开号：US11407717B2

  公开（公告）日：2022-08-09

  The present invention relates to benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof.

  本发明涉及苯并咪唑化合物及其作为IDH1突变体抑制剂的应用，特别是涉及由式（I）代表的化合物、其同系物或其药学上可接受的盐。
• TW2016/2115
  申请人：——

  公开号：——

  公开（公告）日：——